The United Kingdom based research based biopharmaceutical company AstraZeneca Plc has announced that it would soon begin a clinical trial aimed at assessing the possibility of the drug Calquence to be used as a treatment of the exaggerated immune response relates to the with Covid-19 infection, the disease caused by the novel coronavirus, in patients who are severely ill.
The British-Swedish multinational pharmaceutical and biopharmaceutical company said that Calquence is a BTK inhibitor and the drug is presently made use of for the treatment of some specific types of blood cancers.
Authorities in the United States as well as in a number of other countries have already given approval for the use of the drug as a mode of legitimate treatment for adult patients who are suffering from chronic lymphocytic leukaemia in those countries.
This announcement by the company coincides with the situation of the novel coronavirus pandemic ravaging most of the countries of the world has forced drug makers around the world to temporarily put a hold or to slow down the clinical trials for drugs and treatment of other diseases with their complete focus now on finding out and testing all possible drugs and treatment for the fast spreading and potentially deadly Covid-19, the disease caused by the novel coronavirus.
The company is trying to assess and evaluate the effectiveness and safety of adding the drug to best supportive care to reduce mortality through the clinical trials and testing as well as the need for patients in ventilation who are currently facing life threatening symptoms of the Covid-19 disease, the British drugmaker said.
AstraZeneca said that it now expects that the trial will be to open for enrollment in the coming days in the United States and several countries in Europe.
Earlier this month, AstraZeneca and its domestic rival GlaxoSmithKline PLC entered into a deal to set up a testing laboratory to aid in COVID-19 testing with Cambridge University.
(Source:www.nytimes.com)
The British-Swedish multinational pharmaceutical and biopharmaceutical company said that Calquence is a BTK inhibitor and the drug is presently made use of for the treatment of some specific types of blood cancers.
Authorities in the United States as well as in a number of other countries have already given approval for the use of the drug as a mode of legitimate treatment for adult patients who are suffering from chronic lymphocytic leukaemia in those countries.
This announcement by the company coincides with the situation of the novel coronavirus pandemic ravaging most of the countries of the world has forced drug makers around the world to temporarily put a hold or to slow down the clinical trials for drugs and treatment of other diseases with their complete focus now on finding out and testing all possible drugs and treatment for the fast spreading and potentially deadly Covid-19, the disease caused by the novel coronavirus.
The company is trying to assess and evaluate the effectiveness and safety of adding the drug to best supportive care to reduce mortality through the clinical trials and testing as well as the need for patients in ventilation who are currently facing life threatening symptoms of the Covid-19 disease, the British drugmaker said.
AstraZeneca said that it now expects that the trial will be to open for enrollment in the coming days in the United States and several countries in Europe.
Earlier this month, AstraZeneca and its domestic rival GlaxoSmithKline PLC entered into a deal to set up a testing laboratory to aid in COVID-19 testing with Cambridge University.
(Source:www.nytimes.com)
Homepage
Send to a friend
Printable version
Share
